Company Overview - Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation in the biopharmaceutical industry, founded in 1996 [2] - The company collaborates with innovators from academic institutions, research hospitals, non-profits, and biopharmaceutical companies, funding innovation directly and indirectly [2] - Royalty Pharma's portfolio includes royalties on over 35 commercial products and 17 development-stage product candidates, such as Vertex's Trikafta, GSK's Trelegy, Roche's Evrysdi, and others [2] Leadership Appointment - Molly Sawaya has been appointed as Executive Vice President, Head of Human Capital at Royalty Pharma [4] - Molly brings nearly 15 years of HR experience from large global organizations, including Hudson Bay Capital, QBE Insurance Group, Perpetual Limited, and National Australia Bank [1][8] - Her role will focus on fostering a culture of growth and supporting the scaling of the business [8] Business Model - Royalty Pharma funds innovation directly by partnering with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties [2] - Indirectly, the company acquires existing royalties from original innovators, building a portfolio tied to the top-line sales of leading therapies [2]

Core Insights - Royalty Pharma plc has appointed Molly Sawaya as Executive Vice President, Head of Human Capital, effective July 24, 2024 [1][4] Company Overview - Royalty Pharma, founded in 1996, is the largest buyer of biopharmaceutical royalties and a leading funder of innovation in the biopharmaceutical industry [8] - The company collaborates with various entities, including academic institutions, research hospitals, non-profits, and biotechnology companies, to fund innovation [8] - Royalty Pharma's portfolio includes royalties on over 35 commercial products, such as Vertex's Trikafta and GSK's Trelegy, as well as 17 development-stage product candidates [8] Leadership Appointment - Molly Sawaya brings nearly 15 years of HR experience from large global organizations, focusing on creating environments for employee growth and engagement [4][7] - Prior to joining Royalty Pharma, Sawaya was a Managing Director at Hudson Bay Capital, where she led the HR agenda [7] - The CEO of Royalty Pharma, Pablo Legorreta, expressed confidence in Sawaya's ability to enhance the company's culture and support its growth [4]

NEW YORK, July 19, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its second quarter 2024 financial results on Thursday, August 8, 2024 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time that day. Please visit the "Investors" page of the company's website at https://www.royaltypharma.com/investors/events/ to obtain conference call information and to view the live webcast. A replay ...

Group 1 - Royalty Pharma, founded in 1996, is the largest buyer of biopharmaceutical royalties and a key funder of innovation in the biopharmaceutical industry [1] - The company collaborates with various entities, including academic institutions, research hospitals, non-profits, small and mid-cap biotechnology companies, and leading global pharmaceutical companies [1] - Royalty Pharma's portfolio includes royalties on over 35 commercial products and 17 development-stage product candidates, featuring notable therapies such as Vertex's Trikafta and GSK's Trelegy [1] Group 2 - The board of directors of Royalty Pharma has approved a dividend of $0.21 per Class A ordinary share for the third quarter of 2024 [2] - The dividend payment is scheduled for September 13, 2024, to shareholders of record as of August 16, 2024 [4]

The bullish case only gets stronger once investors take into account RPRX's positive earnings estimate revisions. There have been 1 higher compared to none lower for the current fiscal year, and the consensus estimate has moved up as well. From a technical perspective, Royalty Pharma (RPRX) is looking like an interesting pick, as it just reached a key level of support. RPRX recently overtook the 50-day moving average, and this suggests a short-term bullish trend. The 50-day simple moving average is a widely ...

Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? Royalty Pharma (RPRX) , which belongs to the Zacks Financial - Miscellaneous Services industry, could be a great candidate to consider. For the most recent quarter, Royalty Pharma was expected to post earnings of $0.96 per share, but it reported $0.98 per share instead, representing a surprise of 2.08%. For the previous quarter, the consensus estimate ...

Company Overview - Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation in the biopharmaceutical industry, collaborating with various entities from academic institutions to global pharmaceutical companies [2] - The company has a portfolio that includes royalties on more than 35 commercial products, such as Vertex's Trikafta, GSK's Trelegy, and Roche's Evrysdi, as well as 17 development-stage product candidates [2] Upcoming Events - Royalty Pharma is scheduled to participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference on June 11, 2024, at 2:00 p.m. ET, with the webcast accessible on their "Events" page [1]

NEW YORK, June 03, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today that it has priced an offering of $1.5 billion of senior unsecured notes, comprised of the following (collectively, the "Notes"): $500 million of 5.150% Notes due 2029 (the "2029 Notes"); $500 million of 5.400% Notes due 2034 (the "2034 Notes"); and $500 million of 5.900% Notes due 2054 (the "2054 Notes"). The Notes will be guaranteed on a senior unsecured basis by Royalty Pharma Holdings Ltd. The offering is expec ...

Core Viewpoint - Royalty Pharma plc has announced a $1.5 billion offering of senior unsecured notes, which will be used for general corporate purposes [1][2]. Group 1: Offering Details - The offering consists of three tranches: $500 million of 5.150% Notes due 2029, $500 million of 5.400% Notes due 2034, and $500 million of 5.900% Notes due 2054 [1]. - The notes will be guaranteed on a senior unsecured basis by Royalty Pharma Holdings Ltd, with the offering expected to close on June 10, 2024, subject to customary closing conditions [2]. Group 2: Underwriters and Managers - BofA Securities, Citigroup, J.P. Morgan, Morgan Stanley, and TD Securities are acting as joint lead bookrunning managers for the offering [3]. - Additional co-managers include DNB Markets, SMBC Nikko, SOCIETE GENERALE, US Bancorp, and several others [3]. Group 3: Company Overview - Royalty Pharma, founded in 1996, is the largest buyer of biopharmaceutical royalties and a significant funder of innovation in the biopharmaceutical industry [6]. - The company collaborates with various entities, including academic institutions and leading global pharmaceutical companies, and has a portfolio that includes royalties on over 35 commercial products [6].

NEW YORK, May 28, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired an interest in Agios Pharmaceuticals' royalty on Servier's vorasidenib for $905 million in upfront cash contingent on U.S. Food and Drug Administration (FDA) approval of vorasidenib. "We are excited to acquire royalties on vorasidenib, which if approved, would be the first targeted therapy for patients with IDH-mutant glioma," said Pablo Legorreta, founder and Chief Executive Officer of Royalty ...